Following on from information provided to NICE by the company in October 2019, the appraisal of Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1481

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in October 2019, the appraisal of Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
11 October 2019 Suspended. Remit: To appraise the clinical and cost-effectiveness of atezolizumab within its marketing authorisation for non-small cell lung cancer
11 October 2019 The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps

For further information on our processes and methods, please see our CHTE processes and methods manual